Healthcare / BiotechnologyKOSDAQ
$14290.00
-210.00 (-1.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-9.8B · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$311.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-48.8%
↓Gross Margin
100.0%
↑Debt/Equity
0.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-87.4%
FCF CAGR
—
FCF margin
-189707.2%
FCF / Net income
0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.1M · net income $-18.11B · FCF $-13.47B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.1M | $7.1M | $1.63B | $10.29B | $3.58B |
| Net Income | $-18.11B | $-18.11B | $-14.89B | $-11.59B | $-11.41B |
| EBITDA | $-15.90B | $-15.90B | $-11.76B | $-9.59B | $-10.60B |
| EPS | -1120.00 | -1120.00 | -913.03 | -710.70 | -704.75 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -232394.0% | -232394.0% | -773.9% | -102.1% | -334.4% |
| Net Margin | -255057.9% | -255057.9% | -911.9% | -112.5% | -318.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.36 | 0.36 | 0.68 | 0.44 | 0.18 |
| Current Ratio | 2.10 | 2.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-13.47B | $-13.47B | $-9.83B | $-9.52B | $-14.78B |
| Returns | |||||
| ROE | -48.8% | -48.8% | -49.7% | -27.7% | -24.7% |
| Valuation | |||||
| P/B | 6.23 | 6.23 | 3.31 | 4.34 | 3.93 |
| Growth & Yield | |||||
| Revenue Growth | -99.6% | -99.6% | -84.1% | 187.3% | — |
| EPS Growth | -22.7% | -22.7% | -28.5% | -0.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+219.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-913.03 → -1120.00
Residual
+219.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.